Is there a role for prophylactic antibiotic treatment with macrolides in bronchiectasis?;Quelle est la place de l'antibio-thérapie prophylactique par macrolides dans les bronchiectasies?

Revue Medicale Suisse

Volumn 7, Issue 280, 2011, Pages 308-312

  Bochet, Mélanie ^a   Garin, Nicolas ^a   Janssens, Jean Paul ^a   Gerstel, Eric ^a  

^a SERVICE DE MÉDECINE INTERNE GÉNÉRALE   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

MACROLIDE;

ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC THERAPY; ANTIINFLAMMATORY ACTIVITY; BRONCHIECTASIS; DISEASE EXACERBATION; DRUG EFFICACY; HUMAN; IMMUNOMODULATION; PATIENT SELECTION; REVIEW; UNSPECIFIED SIDE EFFECT; ARTICLE;

ANTIBIOTIC PROPHYLAXIS; BRONCHIECTASIS; HUMANS; MACROLIDES;

EID: 79951841722     PISSN: 16609379     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (18)

1. Goeminne P, Dupont L. Non-cystic fibrosis bronchiectasis: Diagnosis and management in 21st century. Postgrad Med J 2010;86:493-501.
2. Barker AF. Bronchiectasis. N Engl J Med 2002;346:1383-93.
3. O'Donnell AE. Bronchiectasis. Chest 2008;134:815-23.
4. Frey JG. Bronchiectasis: A reemerging disease. Rev Med Suisse 2007;3:477-8,80-3.
5. Giamarellos-Bourboulis EJ. Macrolides beyond the conventional antimicrobials: A class of potent immunomodulators. Int J Antimicrob Agents 2008;31:12-20. (Pubitemid 350236720)
6. ** Crosbie PA, Woodhead MA. Long-term macrolide therapy in chronic inflammatory airway diseases. Eur Respir J 2009;33:171-81.
7. King P, Holdsworth S, Freezer N, Holmes P. Bronchiectasis. Intern Med J 2006;36:729-37.
8. * Shinkai M, Henke MO, Rubin BK. Macrolide antibiotics as immunomodulatory medications: Proposed mechanisms of action. Pharmacol Ther 2008;117:393-405.
9. Malhotra-Kumar S, Lammens C, Coenen S, Van Herck K, Goossens H. Effect of azithromycin and clarithromycin therapy on pharyngeal carriage of macrolide-resistant streptococci in healthy volunteers: A randomised, double-blind, placebo-controlled study. Lancet 2007;369:482-90. (Pubitemid 46209315)
10. * Idris SF, Chilvers ER, Haworth C, McKeon D, Condliffe AM. Azithromycin therapy for neutrophilic airways disease: Myth or magic? Thorax 2009;64:186-9.
11. Seemungal TA, Wilkinson TM, Hurst JR, Perera WR, Sapsford RJ, Wedzicha JA. Long-term erythromycin therapy is associated with decreased chronic obstructive pulmonary disease exacerbations. Am J Respir Crit Care Med 2008;178:1139-47.
12. Koh YY, Lee MH, Sun YH, Sung KW, Chae JH. Effect of roxithromycin on airway responsiveness in children with bronchiectasis: A double-blind, placebo-controlled study. Eur Respir J 1997;10:994-9. (Pubitemid 27201800)
13. Tsang KW, Ho PI, Chan KN, et al. A pilot study of low-dose erythromycin in bronchiectasis. Eur Respir J 1999;13:361-4. (Pubitemid 29086834)
14. Davies G, Wilson R. Prophylactic antibiotic treatment of bronchiectasis with azithromycin. Thorax 2004;59:540-1.
15. Cymbala AA, Edmonds LC, Bauer MA, et al. The disease-modifying effects of twice-weekly oral azithromycin in patients with bronchiectasis. Treat Respir Med 2005;4:117-22. (Pubitemid 40613959)
16. Yalcin E, Kiper N, Ozcelik U, et al. Effects of claritromycin on inflammatory parameters and clinical conditions in children with bronchiectasis. J Clin Pharm Ther 2006;31:49-55.
17. Tramper-Stranders GA, Wolfs TF, Fleer A, Kimpen JL, van der Ent CK. Maintenance azithromycin treatment in pediatric patients with cystic fibrosis: Long-term outcomes related to macrolide resistance and pulmonary function. Pediatr Infect Dis J 2007;26:8-12. (Pubitemid 46045744)
18. Pasteur MC, Bilton D, Hill AT. British thoracic society guideline for non-CF bronchiectasis. Thorax 2010;65(Suppl. 1):i1-58.